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Abstract
Background: In order to investigate the epidemiology, molecular characteristics, and distribution of extended-spectrum
β-lactamase (ESBL)- and AmpC-producing Escherichia coli from community-onset infections in Chinese county hospitals.
Methods: E. coli isolates were collected from patients with community-onset infections in 30 county hospitals. ESBL
activity was confirmed by double-disc diffusion. Genetic confirmation and molecular typing of ESBL- and
AmpC-producing isolates was determined by PCR and DNA sequencing. ESBL-positive isolates were further
characterised by multi-locus sequence typing.
Results: Of 550 E. coli isolates, 256 (46.5%) carried ESBL genes and all were of the CTX-M type. The prevalence of
ESBL-producing strains varied from 30.2% to 57.0% across different regions of China. Overall, 12 blaCTX-M subtypes
were detected; the most abundant were blaCTX-M-14 (163/256 isolates, 64.5%), blaCTX-M-55(47/256, 18.4%), and
blaCTX-M-15 (31/256, 12.1%). CMY-2-like AmpC β-lactamases were detected in 11 strains, three of which co-existed
with blaCTX-M. A total of 64 sequence types (STs) were detected in 256 ESBL-producing strains, including nine that
were new. ST131 was the most abundant type (27 isolates, 12.7%), followed by ST69 (14 isolates, 6.6%), ST405
(14 isolates, 6.6%), and ST38 (12 isolates, 5.6%).
Conclusions: This study revealed that the widespread prevalence of ESBLs among outpatient infections has
reached a high level in county hospitals. The CTX-M genotype was most dominant, comprising a variety of
subtypes. This is the first time the incidence of CTX-M-55 has exceeded that of CTX-M-15 in China. No predominant ST
was detected, suggesting that ESBL-producing E. coli strains originate in different clones.
Background
The production of extended-spectrum β-lactamases
(ESBLs) is the main mechanism of resistance to β-lactam
antibiotics in E. coli. ESBLs hydrolyse penicillins, cephalo-
sporins, and aztreonam; however, they are inhibited by cla-
vulanic acid, sulbactam, and tazobactam [1,2]. The enzymes
TEM and SHV were previously recognised as the main
ESBLs. However, CTX-Ms have recently become more
prominent, and are now considered to be the most preva-
lent β-lactamases found in clinical isolates of E. coli globally
[3,4]. A nationwide survey of the United States during
2009–2010 revealed that 91% of ESBL-producing E. coli
strains carried CTX-M-type genes [5]. CTX-M-type ESBLs
are also dominant in European and Asian countries [4,6],
and in China they are the most common ESBLs found in
Gram-negative bacteria isolated from tertiary hospitals
[7-9]. ESBL-producing E. coli strains are a major cause of
community-associated infections [5,10], and their spread
has been well-documented in Europe and North America
[5,11-15]. Strains of ESBL-producing E. coli have been re-
corded in other regions of the world, including Oceania,
Asia, and South America [10,16-18]. Several studies
have characterised ESBL-producing Enterobacteriaceae
in Chinese tertiary hospitals [7,19,20]. A national moni-
toring program of antimicrobial resistance in E. coli
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caused bacteriaemia (mostly nosocomial infections) in
Chinese tertiary hospitals reported an increase in ESBL-
producing E. coli from less than 20% to 72.2% between
2000 and 2011 [21-23]. Another survey of Chinese
tertiary hospitals reported that the incidence of ESBL-
producing E. coli among community-associated intra-
abdominal infections increased from 19.1% in 2002–2003
to 61.6% in 2010–2011 [20]. None of these studies focused
on bacteria isolated from outpatients in primary and non-
central city hospitals. In light of the increasing importance
of ESBL-producing E. coli within communities, it is im-
portant to understand the pattern of antibiotic resistance
and the prevalence of ESBLs in bacterial isolates from pri-
mary and non-central city healthcare institutions that pro-
vide medical services to patients in China.
Most Chinese people live in rural areas or small to
medium-sized cities, and seek their healthcare at county-
level hospitals, which play an important role in China. The
high global prevalence of ESBL-producing E. coli strains
among community-onset infections warrants an urgent
need to investigate the characteristics of antimicrobial re-
sistance in China. This study focuses on community-onset
infections in patients at selected hospitals in seven regions
of China. The purpose was to investigate the antimicrobial
resistance, the incidence of ESBLs and their genetic types,
and the molecular characteristics of E. coli strains isolated
from patients, with the intention of developing strategies
to control and prevent antimicrobial resistance.
Methods
Collection of clinical isolates
Thirty county hospitals were selected for this investiga-
tion (see Additional file 1), which took place between
August 2010 and August 2011, and in total 550 E.coli were
collected. These hospitals are located in 11 different prov-
inces and represent seven geographic regions of China. In
China, hospitals are categorized by the level of service
provision, size, medical technology, medical equipment,
and management and medical quality into 3 subsidiary
levels, primary hospitals, secondary hospitals, tertiary hos-
pitals. All the county hospitals included in this study are
secondary hospitals. Patients were selected for this study
using the following criteria: 1) they attended an outpatient
clinic or emergency department and were diagnosed with
a bacterial infection less than 48 hours after they were
hospitalised; 2) they were not admitted to hospital within
90 days prior to diagnosis; 3) they did not have long-term
indwelling catheters; and 4) and they had not received
antibacterial therapy or had received less than 72 hours of
antibacterial therapy prior to seeing a doctor. Bacterial
strains were isolated from clinical specimens (urine, blood,
sputum, abscesses, and secretions) and identified using
API20 (bioMérieux, Durham, NC, USA). Samples were
collected as part of routine care from outpatients;
pathogens were isolated by standard microbiological
methods by the microbiologists of the participant county
hospitals. All the pure cultures were frozen at -80°C and
shipped to our laboratory for definite identification and
further analysis. The identities of all isolates were ratified
using Matrix-assisted laser desorption ionisation-time of
flight mass spectrometry (MALDI-TOF) as described pre-
viously [24].
Antimicrobial susceptibility testing
Antimicrobial susceptibility was tested using the standard
agar dilution method recommended by the Clinical and
Laboratory Standards Institute guidelines (M100-S21)
[25]. The breakpoint of biapenem was based on the rec-
ommended point of imipenem by CLSI. The following
antimicrobial agents were tested: ampicillin, piperacillin,
cefazolin, cefuroxime, ceftazidime, ceftriaxone, cefepime,
ampicillin-sulbactam, piperacillin-tazobactam, cefoxitin,
biapenem, imipenem, meropenem, amikacin, gentamicin,
ciprofloxacin, levofloxacin, and fosfomycin (Chinese
National Institute for the Control of Pharmaceutical and
Biological Products). ESBL activity was determined by the
double-disc diffusion method using ceftazidime (30 μg),
ceftazidime plus clavulanate (30/10 μg) discs and cefotax-
ime (30 μg), and cefotaxime plus clavulanic acid (30/10 μg)
discs (Oxoid Limited, UK) on Mueller-Hinton agar (Oxoid
Limited, UK) [25]. The results of antimicrobial susceptibil-
ity testing were analyzed by WHONET5.6. The reference
strains used for this study were E. coli ATCC 25922 and
Klebsiella pneumoniae ATCC 700603.
Detection of β-lactamase genes
PCR amplification was used to detect blaCTX-M, blaSHV,
blaTEM, blaOXA, blaVEB, blaPER, and blaGES, blaKPC and
the AmpC β-lactamase genes blaCMY-1, blaCMY-2, and
blaDHA. blaCTX-M group-specific primers for CTX-M-1,
CTX-M-2, CTX-M-8 and CTX-M-9 groups were used
to detect of blaCTX-M genes, and three pair of group spe-
cific primers (OXA-1, OXA-2, OXA-10) for detecting
blaOXA. Genomic DNA of clinical isolates was prepared
using a modified boiling method [26] and this DNA was
used as the template for PCR amplification. PCR products
were separated by electrophoresis using a 1% agarose gel
to identify the amplified DNA fragments. Forward and re-
verse sequencing reactions were performed on an ABI
3730 automated sequencer using ABI Prism BigDye Ter-
minator version 3.1 cycle sequencing (Applied Biosystems,
Foster City, CA, USA). Primers used for PCR detection
and sequencing are listed in Table 1. Gene sequences were
analysed online using BLAST (http://blast.ncbi.nlm.nih.
gov/Blast.cgi) and identified using a β-lactamase database
(http://www.lahey.org/Studies/).
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Molecular typing of E. coli
To determine if ESBL genes were disseminated by clonal
spread or horizontal gene transfer, isolates (n = 213) repre-
senting different regions were analysed by multi-locus se-
quence typing (MLST) following the guidelines found at
http://mlst.warwick.ac.uk/mlst/dbs/Ecoli. Sequence typing
of the housekeeping genes adk, fumC, gyrB, icd, mdh, purA,
and recA was performed on all ESBL-producing E. coli iso-
lates according to Wirth et al. [31]. Sequence types (STs)
were confirmed by comparison with those in the database.
A phylogenetic tree of STs detected in this study was con-
structed using Phylodendron (http://iubio.bio.indiana.edu/
soft/molbio/java/apps/trees/). This tool uses the PHYLIP
(a free package of programs for inferring phylogenies) suite
of programs to generate trees from allelic profile data.
Statistical analysis
Statistical significance was determined by χ2 analysis,
and Fisher’s exact test was used for small sample sizes.
Analyses were performed using SPSS version 20.0 (IBM
Corporation), and a p-value <0.05 was considered to be
statistically significant.
Ethical approval
The Ethics committee of The First Affiliated Hospital,
College of Medicine, Zhejiang University waived the need
Table 1 Primers used for PCR amplification of bla genes
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for formal ethical approval. No institutional review board
approval was necessary, because all the personal informa-
tion of the patients (such as name, height, weight, etc)
was not collected during the investigation and the in-
vestigation did not have any impact on the patient
management. All patients were informed verbally of
our study’s purpose before sending their pathogens to
our laboratory for research.
Results
Patient demographics and specimen types
A total of 550 isolates were collected and confirmed as
E. coli by MALDI-TOF. The majority of the isolates were
recovered from urine specimens (68.5%), with 8.2% from
blood samples, 7.0% from sputum samples, 6.8% from
abscesses, 6.0% from secretions (ascites, pleural fluid),
and 3.5% from other specimens. Females provided 65%
of the isolates. The ages of patients were as follows: ≤17
years, 6.1%; 18–45 years, 39.2%; 46–64 years, 38.3%;
and ≥65 years, 16.4%.
Antimicrobial susceptibility profiles
The results of antimicrobial susceptibility tests for all
isolates and ESBL-producing strains are summarised in
Table 2. All isolates were susceptible to biapenem, imipe-
nem, and meropenem, whereas 94.1%, 93.6%, and 91.0%
of strains were susceptible to fosfomycin, amikacin, and
piperacillin-tazobactam, respectively. In total, 249 strains
produced ESBLs: 100% of these were resistant to ampicil-
lin, with high resistance also to cefazolin (99.6%, n = 248),
ceftriaxone (98.8%, n = 246), ampicillin-sulbactam (61.3%,
n = 153), ciprofloxacin (73.5%, n = 183), and levofloxacin
(68.8%, n = 171).
Genotypic characterisation and geographical distribution
of ESBL- and AmpC-producing isolates
PCR was performed on all 550 isolates to determine the
presence of ESBL and AmpC. These results and the geo-
graphic distributions of the isolates are shown in Table 3.
The findings revealed that 256 isolates (46.5%) carried
ESBL genes, all of which were the CTX-M type: the
CTX-M-9 group (180 isolates) was most abundant,
followed by the CTX-M-1 group (91 isolates). The CTX-
M-2 and CTX-M-8 groups were not detected. Overall, 12
blaCTX-M subtypes were detected: these were blaCTX-M-14
(164 isolates, 65%, including 17 strains co-existed with
other blaESBL or ampC genes), which is now the most
common ESBL in China, blaCTX-M-55 (47 isolates, 17.7%,
including 6 strains co-existed with blaCTX-M-14), blaCTX-M-
15 (30 isolates, 11.7%, including 7 strains co-existed with
blaCTX-M-14 or blaCMY-2 genes), blaCTX-M-3 (9 isolates,
3.5%, including 3 strains co-existed with other blaESBL or
ampC genes), blaCTX-M-24 (9 isolates, 3.5%, including 2
strains co-existed with other blaESBL or ampC genes),
Table 2 Results for susceptibility tests and MICs for E. coli strains (n = 550) isolated from 30 county hospitals
All isolates (n = 550) ESBL-positive (phenotype) isolates (n = 249)
Antibiotic MIC50 (mg/L) MIC90 (mg/L) Susceptible % Resistant % MIC50 (mg/L) MIC90 (mg/L) Susceptible % Resistant %
Ampicillin 256 >256 13.6 85.1 >256 >256 0 100
Piperacillin 64 >256 31.8 49.5 256 >256 0 91
Ampicillin-Sulbactam 16 64 35 39.1 32 64 14.7 61.5
Piperacillin-
tazobactam
8 16 91 2.1 8 32 86.5 4.5
Cefazolin 32 256 46.7 51.1 256 256 0.4 99.6
Cefuroxime 8 256 50.1 47.8 256 256 0 98.5
Ceftazidime 0.5 32 80.4 18.3 4 64 55.6 40.6
Ceftriaxone 0.25 128 55.4 44.2 64 128 0.7 98.5
Cefepime 1 32 77.7 13.5 8 64 54.5 28.9
Cefoxitin 4 32 76.9 15 8 128 61.8 24.7
Biapenem 0.064 0.125 100 0 0.064 0.125 100 0
Imipenem 0.125 0.25 100 0 0.125 0.25 100 0
Meropenem 0.064 0.125 100 0 0.064 0.125 100 0
Amikacin 2 8 93.6 6.1 2 64 89.1 10.2
Gentamicin 16 128 47.2 51.5 64 256 33.5 66.2
Ciprofloxacin 4 64 46.7 51 32 128 24.8 73.3
Levofloxacin 4 32 49.1 46.7 16 64 26.2 68.9
Fosfomycin 1 32 94.1 5.1 1 128 88.6 9.8
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blaCTX-M-65 (4 isolates, 1.6%), blaCTX-M-1 (2 isolates, in-
cluding 1 strain co-existed with blaCTX-M-14), blaCTX-M-12
(1 isolate), blaCTX-M-10 (1 isolate), blaCTX-M-27 (1 isolate),
blaCTX-M-104 (1 isolate), and blaCTX-M-9 (1 isolate). Fifteen
isolates encoded ESBLs from both CTX-M-1 and CTX-M-
9 groups (Table 3, Figure 1).
The prevalence of ESBL-producing E. coli strains var-
ied significantly (p < 0.01). among the different regions
of China, with the highest proportion (57.0%) in North
China and the lowest proportion (30.2%) in East China
(EC). The prevalence of ESBL-producing isolates signifi-
cantly differed among different hospitals within South
China (SC1–SC5) (p < 0.05), the prevalence of ESBL-
producing isolates was high in one hospital (SC4; 72.7%;
8/11 strains) and low in another hospital (SC1; 16.7%; 6/
36 strains), there was a similar situation within different
hospitals in Northwest China (NW1–NW4) (p < 0.05).
There were no statistical differences in the prevalence of
ESBL-producing E. coli strains between different hospi-
tals in the remaining five regions.
CTX-M-14 (CTX-M-9 group) was the most common
ESBL genotype detected in this study; however, the results
suggest that CTX-M-55 (CTX-M-1 group) is also becom-
ing prevalent, with the ratio of the number of CTX-M-55-
positive isolates to the number of ESBL-positive isolates
being 5:8 in SC4, 4:8 in SC5, 6:9 in EC2, and 4:8 in NE1.
By contrast, CTX-M-15 was the predominant genotype in
EC3 and NW2.
There was no statistical difference (p = 0.6) between E.
coli strains isolated from urinary tract infections (n =
Table 3 Geographical distribution of ESBL- and AmpC-producing E. coli isolates in seven regions of China














China (n = 78)
Total
(n= 550)
CTX-M-1 group 16 14 7 10 14 10 2 73
CTX-M-15 7 6 1 2 3 4 23
CTX-M-55 6 6 5 7 10 5 2 41




CTX-M-9 group 32 22 5 3 23 40 36 161
CTX-M-14 29 19 4 3 22 35 35 147
CTX-M-9 1 1
CTX-M-24 2 1 1 2 1 7
CTX-M-27 1 1
CTX-M-65 2 2 4
CTX-M-104 1 1
CMY-2 1 3 2 1 7
DHA-1 2 2
CTX-M-1+9 groups 1 7 2 2 3 15
CTX-M-14+CTX-M-1 1 1
CTX-M-14+CTX-M-3 1 1 2
CTX-M-14+ CTX-M-55 3 2 1 6
CTX-M-14+ CTX-M-15 3 1 1 5
CTX-M-24+ CTX-M-3 1 1
CTX-M-14+OXA-10 1 1
CTX-M-3+ DHA 1 1
CTX-M-14+DHA 2 2
CTX-M-15+CMY-2 1 1 2
CTX-M-24+CMY-2 0 1 1
Totala 53 (57.0) 43 (53.1) 16 (43.2) 13 (30.2) 38 (34.9) 54 (49.5) 39 (50.0) 256 (46.5)
aThe number exclude the strains that only encoded ampC gene.
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324, 46.0% harboured genes for ESBLs), and those isolated
from blood (n = 44, 40.9% harboured genes for ESBLs).
In total, ten isolates encoded CMY-2 ampC genes and
five encoded DHA-1 ampC genes; three of the CMY-2
ampC genes and three DHA-1 ampC genes co-existed
with blaCTX-M.
Characterisation of non-ESBL β-lactamase genes
Genes for the broad-spectrum β-lactamases TEM-1 (347
strains), OXA-1 (35), and SHV-11 (5) were most prevalent
among isolates, and were detected either alone or co-
existing with other enzymes. One strain contained the
gene for the inhibitor-resistant β-lactamase TEM-30 (and
CTX-M-55) and showed no ESBL activity. One strain con-
tained genes for both CTX-M-14 and OXA-10. We be-
lieve this is the first reported detection of OXA-10 in E.
coli in China. The KPC was not detected in this study.
Molecular typing of ESBL-producing E. coli isolates
MLST revealed 64 different STs, and nine new STs that
are not registered in the E. coli MLST database. ST131
was the most abundant type (27 isolates, 12.7%), followed
by ST69 (14 isolates, 6.6%), ST405 (14 isolates, 6.6%), and
ST38 (12 isolates, 5.6%). The sources for the ST131 iso-
lates were distributed across 14 hospitals from seven re-
gions. Among the ST131 isolates, 18 were positive for
CTX-M-14, five were positive for CTX-M-55, three were
positive for CTX-M-15, and one was positive for both
CTX-M-14 and CTX-M-3. Three Northwest hospitals
provided 66.7% of the ST38 strains (n = 12). These three
hospitals are located far from each other in Xinjiang prov-
ince. One hospital accounted for 50% (4/8 isolates) of
ESBL-producing strains. ST38 was the dominant type in
these three hospitals, but was not found in the one hos-
pital in Xinjiang. A phylogenetic tree of STs detected in
this study using a Phylodendron is shown in Figure 2.
Discussion
The findings of this study reveal, for the first time, the
high prevalence of ESBL-producing E. coli associated
with community-onset infections in county hospitals
across China. The results indicate that 46.5% of clinical
E. coli isolates carried genes for ESBLs, and that this
figure varied significantly across the different regions,
Figure 1 National wide distribution of clinical isolates and ESBL-producing E. coli. Geographical location of seven regions from which strains were
collected demonstrated in different colour. The two most dominant genotypes in each region were labelled following the prevalence rate of ESBLs.
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ranging 30.2% to 57.0%. In particular, the proportion of
isolates that carried ESBL genes was 50% or greater in
the North, Northwest, and Southwest regions of China.
PCR amplification revealed a high diversity of CTX-M-
type ESBLs in China, with 12 subtypes detected. The re-
sults showed that CTX-M-14 was the most abundant of
those CTX-M enzymes detected, and that it is prevalent
across China. This is supported by previous studies that
have reported the prevalence of ESBLs in isolates from
both community-associated and hospital-acquired infec-
tions in Chinese tertiary hospitals, and also in healthy
people from large cities [7,8,32].
A developing characteristic of ESBL epidemiology in
several hospitals is the emergence of CTX-M-55 as a
dominant genotype. This is the first study to report that
the abundance of clinical isolates in China containing
CTX-M-55 have exceeded those with CTX-M-15 as the
second most common genotype. In 2009, CTX-M-55
was detected in only two of 49 CTX-M-1 group E. coli
strains in Guangzhou Province in South China [33]. Fol-
lowing this report, there were limited investigations into
the presence of CTX-M-55 in Chinese clinical isolates.
However, Hu et al. recently reported that eight CTX-M-
55 strains were detected from 17 CTX-M-1 group E. coli
isolates from the faeces of healthy humans in Hangzhou
(Zhejiang Province) [32].
CTX-M-15 differs from CTX-M-55 by a single amino
acid substitution of Ala-77-Val. CTX-M-55 was first
detected in clinical isolates of E. coli and K. pneumonia
from Thailand in 2005 [34], and was subsequently found
in Salmonella spp. in China, the United States, Korea,
and Switzerland [35-37]. Although CTX-M-55 is widely
distributed in E. coli strains isolated from pets and food-
producing animals, its range currently appears restricted to
specific geographic regions, mainly in Asia [15,34,38-41].
Two previous studies of the epidemiology of ESBL-
producing E. coli strains in food-producing animals in
China reported that CTX-M-55 was the second (26.1%, 29/
111) and third (18.5%, 10/54) most common genotype,
both following CTX-M-14 [39,42]. A further study showed
that CTX-M-55 was the second most common (25%, 27/
108 strains) genotype detected among ESBL-producing E.
coli strains isolated from healthy ducks and environmental
samples from a duck farm in South China [40]. These find-
ings suggest that CTX-M-55 has already transferred from
animals to humans, and spread among both healthy indi-
viduals and patients in China, and that this particular β-
lactamase may be displacing blaCTX-M-14 as the most com-
mon genotype in some regions.
Drug resistance in E. coli can be transferred horizontally
between strains that are common to food-producing ani-
mals and humans. E. coli can also transfer resistance genes
to bacteria that are part of the commensal intestinal flora,
and it may serve as an important reservoir for these trans-
missible traits [43-47]. Winokur et al. reported plasmid
transfer of β-lactamase genes between Salmonella and E.
Figure 2 Phylogenetic tree of STs detected in this study using Phylodendron. This tool uses the PHYLIP suite of programs to generate trees from
allelic profile data. Phylogenetic tree generated in this study indicated there was no concentrated distribution of STs in ESBL-producing genotypes.
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coli, and suggested that they may have been transmitted
between food-producing animals and humans [44]. Fey
et al. reported the acquisition of ceftriaxone-resistant Sal-
monella enterica serotype typhimurium by a 12-year-old
boy from cattle [45]. This finding highlights the potential
threat to public health through the transfer of highly re-
sistant bacterial strains from livestock to humans, particu-
larly farmers, ranchers, and animal handlers [45]. Findings
from this study, and others, suggest that CTX-M-55 can
be transmitted from animals to humans. Most outpatients
in county hospitals live in rural areas and are likely to have
contact with infected food-producing animals and farm
sewage. Further investigations are needed to test this hy-
pothesis and resolve the mechanism by which blaCTX-M-
55 transfers to, and exists in, humans.
In this study, 64 different STs (including nine new STs)
were detected among 213 ESBL-producing E. coli isolates,
and ST131 was the most abundant type (12.7%). These
findings are similar to those from a tertiary hospital inves-
tigation, which reported that 9.6% of 94 blaCTX-M-14- and
blaCTX-M-15-containing E. coli strains belonged to ST131
[48]. An investigation of ESBL-producing E. coli isolated
from river samples and the faeces of healthy humans
found that 14.4% (20/139) of isolates belonged to ST131
[32]. The findings indicate that no particular ST of E. coli
is predominant in China, unlike European and North
American countries where there is a higher prevalence of
ST131 [6]. For example, 53% of ESBL-producing E. coli
isolates belonged to ST131 in the United States [5]. A
study from Calgary for the period 2000–2007 revealed that
E. coli clone ST131, which produces CTX-M-15, was an
important cause of community-onset bacteraemia, with its
incidence increasing from 6% (1/18) in 2000–2003 to 41%
(20/49) in 2004–2007 [49]. In one region of the United
Kingdom, 64% of community-acquired cefpodoxime-
resistant E. coli infections were caused by ST131 [50].
Similarly, data from Belgium covering the period 2006–
2007 shows that 62% of CTX-M-15-carrying E. coli caus-
ing community-acquired infections belonged to ST131.
[51] In France, 25% of community-onset ESBL-producing
E. coli infections belonged to ST131 [13].
No dominant ST type was detected in any region;
however, in Northwest China, 19.5% (8/41) of isolates
belonged to ST38 (detected in three of four hospitals).
These four hospitals are all located in Xinjiang province,
and are far away from each other. Results indicated that
164 blaCTX-M-14-containing strains clustered into 40 dif-
ferent STs, and 47 blaCTX-M-55-containing strains were
scattered between 22 different STs. There was no con-
centrated distribution of STs in these two, or any other,
ESBL-producing genotypes (Figure 2). The results indi-
cate no evolutionary convergent relationships among
ESBL-producing E. coli in Chinese hospitals, and sug-
gest that the clonal dissemination of ESBL-producing
strains is complicated in China and requires further
investigation.
This study provides the first report of an OXA-10-like
β-lactamase sequence detected in a member of the En-
terobacteriaceae in China, although it was previously re-
ported in Pseudomonas aeruginosa [52]. OXA-10 has also
been recorded in multi-drug-resistant clinical isolates of E.
coli, K. pneumonia, and Proteus. mirabilis [53-55]. OXA-
10 is a class D broad-spectrum β-lactamase that hydroly-
ses oxacillin, methicillin, and cloxacillin, and is inhibited
by sodium chloride and clavulanic acid [56]. This β-
lactamase was first detected in P. aeruginosa in 1988 [56],
and has a similar function to OXA-2 as the parent of
OXA-type ESBL, the extended-spectrum variant was con-
tinually found in P. aeruginosa during the past two decades,
although it has not been detected in Enterobacteriaceae
[57,58]. The detection of OXA-10 in the Enterobacteriaceae
reported here, and in other studies, suggests further investi-
gations are needed into the origin of this P. aeruginosa-de-
rived β-lactamase and its transmission.
Conclusions
In summary, this study reports high rates of ESBL-
producing isolates of E. coli community-associated infec-
tions in county hospitals in China; although the preva-
lence was lower than in tertiary hospitals. The CTX-M
ESBL was the dominant enzyme, and CTX-M-14 was
the major molecular type detected in community-onset in-
fections. A diverse range of STs was detected, and no evo-
lutionary convergent relationship among ESBL-producing
E. coli was found. We also report the detection of the
OXA-10 type of ESBL in clinical isolates of E. coli. These
evolutionary characteristics of ESBL epidemiology in clin-
ical strains of E. coli may complicate the future manage-
ment of antibiotic resistance in China if no effective
measures are taken. Further investigations are needed to
resolve the mechanisms underlying the increasing inci-
dences of CTX-M-55 and the emergence of OXA-10 in
strains of E. coli in county hospitals.
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